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OBJECTIVES We sought to assess the impact of intermittent atrial fibrillation (AF) on health-related
quality of life (QoL).
BACKGROUND Intermittent AF is a common condition with little data on health-related QoL questionnaires
to guide investigational therapies.
METHODS Outpatients from four centers, with documented AF (n 5 152), completed validated QoL
questionnaires (Medical Outcomes Study Short Form 36 [SF-36], Specific Activity,
Symptom Checklist, Illness Intrusiveness and University of Toronto AF Severity Scales).
Comparison groups were made up of healthy individuals (n 5 47) and four cardiac control
groups: published (n 5 78) and created for study (n 5 69) percutaneous transluminal
coronary angioplasty (PTCA); published heart failure (n 5 216) and published post-
myocardial infarction (MI) (n 5 107).
RESULTS Across all domains of the SF-36, AF patients reported substantially worse QoL than healthy
controls (1.3 to 2.0 standard deviation units), with scores of 24%, 23%, 16% and 30% lower
than healthy individuals on measures of physical and social functioning, mental and general
health, respectively (all p , 0.001). Patients with AF were either significantly worse (p ,
0.05, published controls) or as impaired (study controls) as either PTCA or post-MI patients
on all domains of the SF-36 and the same as heart failure controls on SF-36 psychological
subscales. Patients with AF were as impaired or worse than study PTCA controls on measures
of illness intrusiveness, activity limitations and symptoms. Associations between objective
disease indexes and subjective QoL measures had poor correlations and accounted for ,6%
of the total variability in QoL scores.
CONCLUSIONS Quality of life is as impaired in patients with intermittent AF as in patients with significant
structural heart disease. Patients’ perception of QoL is not dependent on the objective
measures of disease severity that are usually employed. (J Am Coll Cardiol 2000;36:1303–9)
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Atrial fibrillation (AF) is the most common symptomatic
arrhythmia (1,2) and results in a high rate of consumption
of medical care resources (3). There is reasonable consensus
with regard to the prevention of cardioembolic events from
AF; the other current goals of therapy are largely based on
the amelioration of symptoms and functional capacity and
reduction of disability and consumption of healthcare re-
sources.
Therapy to achieve and maintain sinus rhythm is often
administered to patients, particularly to those with inter-
mittent paroxysmal (self-terminating) or persistent (requir-
ing therapy to terminate) AF. Such therapy is frequently
ineffective and may cause adverse effects, occasionally seri-
ous (4,5). As a result, many patients with intermittent AF
are referred to tertiary care referral centers for therapy,
which may include investigational therapies, including de-
vice, ablative (surgical or catheter) and investigational drug
approaches. Most of these investigational therapies use
unambiguous physiological measures as end points to estab-
lish therapeutic efficacy. Such measures include the fre-
quency and duration of AF episodes, underlying ventricular
function, functional capacity during sinus rhythm and dur-
ing AF (6,7), heart rate and maximum volume of oxygen. In
a nonfatal condition such as intermittent AF, the use of
physiological measures to assess therapeutic efficacy is based
on an assumption that these measures reflect the health-
related contributions of how patients subjectively feel (8).
This belief has never been formally tested. In addition to a
possibly tenuous connection between objective physiological
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measures and patient-perceived subjective factors, there is
also a growing appreciation that subjective patient-perceived
dimensions of the severity of an illness are themselves
important considerations in weighing the benefits versus the
risks for any therapy.
To date, there has been no systematic study of subjective
quality of life (QoL) in a relatively large, consecutive group
of patients with AF. The lack of such health-related QoL
data is usually based on a perception that such data is
difficult to interpret, does not have normative or cardiac
disease related controls and does not contain adequate data
to allow for adequate sample size estimations.
Many of these concerns are valid, and they led to the
impetus for this study. We hypothesized that QoL in
patients with intermittent AF would be significantly im-
paired compared with normal age-matched controls and
would be similar to those who have significant coronary
disease (with prior myocardial infarction [MI], heart failure
or the need for angioplasty) but not correlate with more
objective, conventional clinical parameters. To test these
hypotheses, patient-perceived QoL using a variety of vali-
dated questionnaires, as well as objective measures of disease
severity, was assessed in patients with intermittent AF who
were referred to one of four tertiary care centers.
METHODS
AF patients. Consecutive outpatients over the age of 18
years who could read English or German and had no
cognitive or sensory limitations were asked to participate in
this study. To enter this study, eligible patients had to have
at least one documented episode of paroxysmal (spontane-
ously self-terminating) or persistent (intervention required
to successfully restore sinus rhythm) AF. Patients in per-
manent AF with continuous duration lasting longer than six
months were excluded. Also excluded were patients who
received an implantable cardioverter defibrillator or atrial
defibrillator. Patients with AF due to secondary causes
(postcardiovascular surgery, hyperthyroidism) were also ex-
cluded. Patients were referred to one of four outpatient
arrhythmia clinics (St. Luke’s Hospital, Milwaukee, Wis-
consin; St. Michael’s Hospital, University of Toronto,
Toronto, Canada; St. George’s Hospital, London, England
and University of Bonn Hospital, Bonn, Germany).
Cardiac control patients. In an effort to acquire a control
group with stable and significant coronary artery disease,
consecutive patients from an outpatient postangioplasty
clinic at one of the tertiary care referral centers that also
entered patients into the main study (St. Michael’s Hospi-
tal) were identified. These patients were seen at the time of
their routine six-month postangioplasty clinic visit between
June 1997 and February 1998. Those patients without
cognitive deficits, who could read English, were eligible to
participate. Patients with documented AF, an artificial heart
valve, pacemaker or ventricular defibrillator were also ex-
cluded. In addition, other cardiac comparative groups were
assessed from published data sources; an angioplasty group
was obtained from a published case series that included an
Medical Outcomes Study Short Form 36 (SF-36) question-
naire (n 5 79) (8,9), and both post-MI (n 5 107) and heart
failure (n 5 216) groups were available from the published
SF-36 data manual (10).
Healthy subjects. A healthy individuals control group was
also used for comparison. Patients scheduled for routine
health examination, without any documented cardiovascular
disease or other serious illness, were identified at two
outpatient clinics (Toronto and London). English-speaking
people over the age of 18 years without any diagnosed
psychiatric illness were eligible to participate. Relevant
medical history and medications were recorded to confirm
health status independently.
Outcome measurements. Patient characteristics and clin-
ical history, including age, gender, left ventricular function,
antiarrhythmic medications, history of hypertension, history
of heart failure, echocardiographic left atrial diameter and
New York Heart Association classification (NYHA) were
collected for each patient. Patients were given question-
naires evaluating QoL and symptom burden in the arrhyth-
mia clinic and were instructed to mail them back within two
weeks in postage paid envelopes.
QoL questionnaires. In addition to recording standard
demographic variables, a number of validated outcome
measures were used. The SF-36, a widely used generic
health scale with standardized scores ranging from 0 to 100
was used to measure physical functioning, role functioning,
social functioning, mental health, vitality, pain and general
health perceptions (10). To measure functional capacity, the
Goldman Specific Activity Scale (SAS) (11), modified using
a continuous scale to increase its discriminatory power, was
included. Arrhythmia-related symptom frequency and se-
verity were assessed by the Symptom Checklist (12). Al-
though developed to assess symptoms referable to arrhyth-
mias, this was also offered to healthy controls and to one of
the post-percutaneous transluminal coronary angioplasty
(PTCA) cardiac control groups. The degree of life disrup-
tion attributable to illness was measured by the Illness
Intrusiveness Ratings Scale (13). This scale was developed
to measure the degree of life disruption in social, emotional,
physical, affective and spiritual spheres caused by a chronic
illness. The questions stem was altered to assess data from
Abbreviations and Acronyms
AF 5 atrial fibrillation
AV 5 atrioventricular
MI 5 myocardial infarction
NYHA 5 New York Heart Association functional
classification
PTCA 5 percutaneous transluminal coronary angioplasty
QoL 5 quality of life
SAS 5 Goldman Specific Activity Scale
SD 5 standard deviation
SF-36 5 Medical Outcomes Study Short Form 36
1304 Dorian et al. JACC Vol. 36, No. 4, 2000
Quality of Life in AF October 2000:1303–9
this scale when administered to the healthy normal control
group. The University of Toronto Atrial Fibrillation Sever-
ity Scale, a locally constructed, 14-item disease specific scale
developed to capture subjective and objective ratings of AF
disease burden, including frequency, duration and severity
of episodes, was also included (14). This scale also includes
a brief health care utilization component that assesses the
number of emergency room visits, hospitalizations, special-
ist visits and cardioversions for AF in the previous year.
The study was approved by each institution’s local ethics
review board.
Statistical analyses. The sample of 152 patients was ade-
quately powered to detect at least a 10-point difference
between patients with AF and control patients on most
SF-36 subscales using a two-tailed test with 80% power
(15). This difference is considered moderate in size and is
within half of a standard deviation (SD) of most subscales of
the SF-36 in normative populations.
Quality of life outcomes are expressed as means 6 SD.
To determine differences in the various QoL responses by
group, continuous response variables were compared using
analysis of variance. Since it has been previously shown that
QoL is dependent on age and gender (15), these variables
were included as possible explanatory variables. Bonferoni
correction was used for multiple comparisons where appro-
priate. P values ,0.05 associated with the group variable
were considered statistically significant. Preliminary analy-
ses showed no significant QoL differences between patients
at the four centers, so data were pooled for analysis.
RESULTS
Of the 194 patients with AF consecutively referred to one of
the four participating centers, 175 met entry criteria. From
these, 152 (87%) had complete data for analyses (8%, 35%,
23% and 35% from Milwaukee, Toronto, London and
Bonn, respectively). The mean age of the group was 58 6
12 years, and 73% were men; AF was paroxysmal in 60.5%
and persistent in 39.5%.
Ninety-nine percent of the entire AF group was NYHA
class I or II with respect to exercise capacity when patients
perceived themselves to be in sinus rhythm. This is similar
to the NYHA status of the post-PTCA study-created
control group who were all NYHA class I or II. During
perceived or documented AF, exercise function was poorer
with only 38% in NYHA class I. A minority of patients had
other cardiac arrhythmias such as a history of Wolff-
Parkinson-White syndrome (2%), atrioventricular (AV)
nodal reentrant tachycardia (2%), other supraventricular
tachycardias (5%) or atrial flutter (16%). Five percent had
had prior PTCA, 4% bypass surgery and 4% heart valve
replacement. The mean left ventricular ejection fraction in
the 57% in whom it was available was 61 6 16%; mean LA
diameter was 42 6 6 mm (Table 1).
Seventy-six percent of the patients were on anticoagu-
lants at the time of assessment, 61% were receiving some
antiarrhythmic therapy, and 42% were taking AV nodal
blocking drugs. Whether patients were on any antiarrhyth-
mic drugs or AV nodal blocking drugs was not related to
any QoL outcome measured. Most patients (90%) had some
symptoms during AF, including palpitations in 68%, fatigue
in 62% and shortness of breath in 60%.
More than half the patients (60%) had AF episodes,
subjectively, more often than once per week; 22% had
episodes between once per week and once per month; and
18% had episodes less often than once per month. The
average duration of the episodes, as judged by the patients,
was 23% lasting ,1 h, 39% lasting between 1 h and the
whole day and 39% lasting more than a day at a time
(University of Toronto Arrhythmia Scale).
Fifty-one percent had been cardioverted on at least one
occasion in the past, with a mean of 1.2 6 1.4 cardiover-
sions overall. Nearly half of all patients (44.6%) had been to
the emergency room at least once in the previous year, and
51% had been hospitalized for their AF at least once in the
previous year. Most patients had been to visit their specialist
on at least one occasion (89.8%) with a median of three
visits per year for each patient. A third of all patients
(33.1%) had five or more specialist visits in the previous year
(University of Toronto Arrhythmia Scale).
Healthy control group. The group of 47 healthy subjects
was 45% men with a mean age of 54 6 14 years (Table 1).
There was a significantly greater proportion of men in the
AF group compared with the group of healthy subjects (p 5
0.0025), and AF patients were significantly older than
healthy subjects (p 5 0.0329). Ventricular function infor-
mation was unavailable from the healthy individuals al-
though their exercise tolerance as measured by the SAS was
excellent (92 6 14, range 58 to 100).
Cardiac control patients. The clinical characteristics of
the control groups are listed in Table 1. Cardiac controls, all
of whom had coronary disease with prior angioplasty, were
significantly older (p 5 0.001) and had worse left ventricular
function (p 5 0.004) than patients with AF.
Health-related QoL. The scores for the generic SF-36
instrument for which data is available in all control groups
are presented in Table 2. The data for the Illness Intrusive-











Age (yrs) 58 6 12 62 6 9* 54 6 14
Gender (% male) 73% 79% 44%*




(n 5 86), 61 6 16 (n 5 47), 54 6 12*
*p , 0.05 compared with AF group. All values are mean 6 SD.
AF 5 atrial fibrillation; Healthy Subjects 5 individuals without serious illness or
cardiac history from St. Michael’s Hospital, Canada; PTCA 5 percutaneous
transluminal coronary angioplasty; PTCA Patients 5 Patients 6 months after
percutaneous transluminal coronary angioplasty.
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ness Scale (a measure of general health and well being), the
Symptom Activity Scale (a measure of physical functioning)
and Symptom Burden (based on symptom frequency and
symptom severity from a symptom checklist) are presented
for the study group and the control populations created
particularly for this study in Table 3.
QoL in AF patients compared with healthy controls.
Across all scales, both the disease specific and generic QoL
was significantly worse in the AF patients compared with
the controls. The magnitude of these differences was ap-
proximately a full standard deviation unit in almost all cases.
Using a modified stem to reflect their normal status, the
healthy control group provides an estimation of “ceiling”
effects when these disease-based scales were applied with
scores on illness intrusiveness of 28 6 19 (maximum 30),
global life satisfaction of 80 6 12 (maximum 100) and
symptom checklist frequency of 10 6 6 (minimum 0) and
8 6 5 on severity (minimum 0). All of these numbers are
significantly elevated in the AF patients with, for example,
illness intrusiveness rising to 35 6 15 and symptom severity
rising to 19 6 8 and symptom frequency rising to 22 6 10.
Similarly, the Goldman Specific Activity Scale, a measure of
functional capacity was 93 6 11 in healthy controls, falling
to 75 6 20 in AF patients. There were similar profound (1.3
to 2.0 SD unit) differences on measures on SF-36 instru-
ments subscales in AF patients compared with healthy
controls (Table 2).
QoL in AF patients compared with cardiac controls.
The published PTCA control group had better QoL scores
than the PTCA control group created for the study. The
PTCA study-created cohort were all derived from the one
Canadian center (which entered 35% of the AF study
group) and perhaps reflects a significantly greater symptom
burden before intervention in patients referred for tertiary
care services in Canada (16). Nonetheless, across all do-
mains of the SF-36, AF patients scored either worse than
(published group) or the same as study-created PTCA
patients, despite the fact that PTCA patients were older,
had worse left ventricular function and required a major
procedural intervention. The relative impairment of QoL in
AF patients compared with angioplasty control groups was
similar in both physical and psychological domains of the
generic SF-36 scale.
In the congestive heart failure comparator group, physical
functioning scores were all worse than the AF group, with
the exception of vitality, which was as impaired in the AF
group as in patients with heart failure (47 6 21 vs. 44 6 24,
p 5 NS). In contrast, psychological and social scales were
either significantly better (mental health 68 6 18 vs. 75 6
21, p , 0.01) or the same (role emotional, social) in
congestive heart failure patients compared with the AF
group. Similarly, AF patients, despite younger age and
better left ventricular function, were either significantly
more impaired (general health, vitality, mental health, social




















General health 54 6 21 51 6 23 65 6 22† 47 6 24† 59 6 19‡ 78 6 17†
Physical functioning 68 6 27 60 6 29 76 6 25‡ 48 6 31† 70 6 26 88 6 19†
Role physical 47 6 42 47 6 45 71 6 39† 34 6 40† 51 6 39 89 6 28†
Vitality 47 6 21 48 6 26 60 6 20† 44 6 24 58 6 19† 71 6 14†
Mental health 68 6 18 74 6 18 75 6 16† 75 6 21† 76 6 16† 81 6 11†
Role emotional 65 6 41 64 6 44 83 6 35† 64 6 43 73 6 38 92 6 25†
Social functioning 71 6 28 74 6 29 87 6 21† 71 6 33 85 6 21† 92 6 14†
Bodily pain 69 6 19 68 6 17 73 6 27 63 6 31‡ 73 6 25 77 6 15‡
*p , 0.05, compared with AF patients; †p , 0.001, compared with AF patients; ‡All values represent raw mean scores 6 SD,
higher scores represent better quality of life.
AF 5 atrial fibrillation patients; CHF 5 congestive heart failure patients, from Ware, JE, Jr. (15); Post-MI 5 patients with
recent myocardial infarction, from Ware, JE, Jr. (15); PTCA Patients\ 5 patients 6 months after percutaneous transluminal
coronary angioplasty, from St. Michael’s Hospital, Toronto, Canada; PTCA Patients¶ 5 patients after percutaneous
transluminal coronary angioplasty from Krumholz et al. (9); SF-36 5 Medical Outcomes Study Short Form 36.











General Health and Well-Being Global Life Satisfaction* 62 6 20 68 6 18‡ 80 6 12†
Illness Intrusiveness 35 6 15 39 6 17 28 6 19‡
Functional Capacity (SAS) Functional Capacity (SAS)* 75 6 20 72 6 22 93 6 11†
Symptom Burden Symptom Frequency (SCL) 22 6 10 16 6 10‡§ 10 6 6†
Symptom Severity (SCL) 19 6 8 13 6 9§ 8 6 5†
All values represent raw mean scores 6 SD; *Higher scores represent better QoL; †p , 0.001, compared with AF patients; ‡p ,
0.05, compared with AF patients; §p , 0.01, compared with AF patients.
AF 5 atrial fibrillation; PTCA Patients\ 5 patients 6 months after percutaneous transluminal coronary angioplasty, from St.
Michael’s Hospital, Toronto, Canada; SAS 5 Specific Activity Scale; SCL 5 symptom checklist.
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function) or equivalently impaired (physical function, role
physical, role emotional and bodily pain) as post-MI pa-
tients.
The QoL instruments for which study-created compar-
ator groups only can be used show similar trends. Atrial
fibrillation patients were the same as the PTCA group on
illness intrusiveness and the Specific Activity Scale and
significantly worse than the PTCA group on global life
satisfaction (62 6 20 vs. 68 6 18, p , 0.05). The AF group
was also significantly worse on measures of symptom fre-
quency and severity than the PTCA group (22 6 10 vs.
16 6 10 and 19 6 8 vs. 13 6 9, both p , 0.01).
Relationship between objective measures of disease and
subjective illness states. In a separate analysis, we exam-
ined potentially confounding variables that may also affect
QoL. Variables such as left ventricle grade on echocardiog-
raphy, ejection fraction, frequency and duration of AF
episodes (from the University of Toronto AF Severity
Scale), number of prior cardioversions, NYHA class and
antiarrhythmic medications were examined by univariate
analyses to determine if these variables were related to
measures of physical functioning (SF-36), mental health
(SF-36) or global well being. Significant variables identified
by univariate analyses were entered into a hierarchical
regression analysis controlling for age and gender. New
York Heart Association class and AF episode frequency
were significantly related to SF-36 physical function scores
(p , 0.02 and p , 0.04 for regression coefficients, respec-
tively) but together accounted for only ,6% of total
variability in scores (r2 5 0.03 to 0.02). Similarly, both
variables also predicted global well being (p , 0.01, p 5
0.05, respectively) but accounted for only 8% of variability in
total well being scores. Table 4 provides all independent
correlation coefficients for each measure and QoL domains
and shows the relatively poor correlation of QoL scores with
‘objective’ indexes.
DISCUSSION
The main result of this trial is that health related QoL, in an
unselected consecutive population of tertiary care referred,
symptomatic, relatively young patients with intermittent
AF, is markedly impaired compared with a healthy index
population and is similar on most scales to the health
impairment seen in four different cardiac control groups
(after angioplasty [published or study-created], heart failure
and postinfarction), all of whom have a greater degree of
structural heart disease. As well, we have found that the
extent of subjective QoL impairment is poorly related to
traditional objective measures of illness severity, such as
frequency, duration, cardiac dysfunction and NYHA class.
Furthermore, the other more disease-related impairments in
AF patients (illness intrusiveness, physical activity and
specific symptoms) were as poor or worse than that seen in
the study-created post-PTCA comparator group.
Objective versus subjective measures. The most com-
monly employed methods to evaluate the success of thera-
pies in AF are the time to first recurrence of documented
AF or other measures focused around the frequency or
duration of events. Although such end points are unambig-
uous, their use implies that it is the frequency and duration
of the arrhythmia per se that determines the extent of
patient suffering. Our data suggests that from the patient’s
subjective perspective, this may not be so.
Although it may seem counterintuitive that physical
dimensions of QoL are poorly related to exercise capacity
and measures of left ventricular function, this result is
consistent with previous findings that demonstrate that
formal measures of left ventricular dysfunction are poorly
related to NYHA class and exercise capacity in a population
of heart failure patients (17). Our results suggest that the
subjective patient-perceived effects of AF on QoL not only
extend to the physical and somatic dimensions but also
impact on the social and emotional aspects of life and overall
health quality. Such global impairment of life quality may be
characteristic of many other chronic relapsing illnesses with
an unpredictable clinical course. Our results suggest that,
like many chronic conditions, AF leads to impairment of all
domains of QoL independent of the objective severity of the
underlying disease.
Perhaps surprisingly, patients with recent PTCA, had
similar or greater QoL impairment compared with the AF
patients. This was despite the fact that they were signifi-
cantly older and tended to have worse left ventricular
function. The AF population in this study had QoL scores












General health (SF-36) 0.06† 0.01 0.00 0.05† 0.00
Mental health (SF-36) 0.00 0.02 0.03† 0.00 0.00
Physical function (SF-36) 0.04† 0.01 0.02 0.04† 0.02
Social function (SF-36) 0.02 0.00 0.01 0.03† 0.01
Functional capacity (SAS) 0.05† 0.00 0.04† 0.04† 0.04†
Cardiac symptom frequency (SCL) 0.00 0.00 0.03 0.05† 0.01
Cardiac symptom severity (SCL) 0.00 0.00 0.05† 0.05† 0.00
*Correlation coefficients between objective and subjective indexes. Despite statistical significance, the highest correlation accounts
for no more than 6% of variance in the general health domain. See text for further discussion. †p , 0.05.
AF 5 atrial fibrillation; NYHA 5 New York Heart Association; SF-36 5 Medical Outcomes Study Short Form 36.
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similar to those post-MI (15), and, at least on the Illness
Intrusiveness Scale, AF patients perceived their illness to be
as intrusive in their everyday lives as patients on chronic
hemodialysis (13).
Other studies. This is the largest study of QoL in a series
of consecutive patients with any form of AF. There is
limited serial QoL data available from small, highly selected
case series assessing the effects of AV junction ablation in
patients with chronic AF. These studies have shown that
the baseline measures of impairment in QoL are similar in
magnitude to those seen in the much larger samples of this
study. More importantly, these trials have generally shown
very significant improvements in QoL commensurate with
therapeutic interventions. These improvements suggest the
inherent validity of the QoL measures. For example, in 22
patients with chronic AF assessed before and six months
after ablation, QoL impairment on some of the SF-36
subscales improves, for example, on the social functioning
scale, from 60.7 6 18 to 82.1 6 17, a return to a level
similar to that of published age-matched normal controls
(12,15). Other physical functioning subscales showed sim-
ilar dramatic improvements. Brignole et al (18,19) showed
that catheter AV junctional ablation for patients with
chronic AF led to significant improvement in locally con-
structed, and less well validated, symptom burden scales
(palpitations, dizziness, breathlessness) but not to changes
in published validated instruments. Lastly, from a larger
group of 107 patients selected for AV nodal ablation,
general QoL improved and health care utilization decreased
after ablation (20). The scale used for health care measure-
ment in this study, however, was locally constructed and of
unclear validity. Nonetheless, the data supports that QoL
measurement is a bonafide end point for efficacy assessment
in these intervention trials with an unknown amount of
selection bias with respect to the relatively small numbers of
patients entered into these trials.
Implications for research. The results of this study do not
necessarily imply that eliminating AF or markedly reducing
its frequency and duration is unimportant or that the latter
may not contribute in any way to patient well being. Atrial
fibrillation itself may independently cause worsening of left
ventricular dysfunction (2), increased stroke risk (21) and
increase health care resource consumption (3), apart from
the subjective dimensions of illness. However, our observa-
tions emphasize that the subjective dimensions of an illness
are important in the assessment of disease severity and
provide data that will help enhance the use of these
measures in planning the study of patients with AF. We
have found that, despite relatively preserved left ventricular
function, perceived symptoms during AF are significant and
commensurate with symptoms in populations with more
‘disease’ as conventionally defined. The data also provide
opportunities for the sample size estimates with respect to
therapeutic interventions. The minimally appropriate effect
size for interventions based on QoL is not clear. Nonethe-
less, in the psychometric literature, it is generally felt that
changes in the order of 0.5 SD units are significant, and at
least moderate in nature (22). We would emphasize that the
inherent difficulty in interpreting individual QoL scales is
no different than similar difficulties that are inherent in
assessing biological measures with respect to individual
patient symptomatology (23). Nonetheless, for a
population-based viewpoint, the data provided by this larger
consecutive series allows sample size estimates for interven-
tion trials, in exactly the types of patients now typically
entered into trials of investigational AF therapies.
Study limitations. Since all the data has been derived from
tertiary care referral centers, there is concern over potential
selection bias. However, all patients were consecutive and
unselected, other than by referral to a tertiary care center.
Virtually all investigational AF therapies are likely to be
initiated at investigational centers in similar tertiary care
referral centers. The controls used for comparative analysis
in this study are important. We have used a standard,
population-based normative control data for both heart
failure and MI. An angioplasty population was chosen as a
comparator largely on the basis that such a population
marks a group of patients who have coronary artery disease
and generally continue to consume medications and health
care resources (24). As well, given the nature of the
intervention, one may well expect significant existential
concerns on the part of patients that would impact health-
related QoL. To help make the PTCA comparator group
more balanced with respect to selection bias via referral to a
tertiary care center, two such groups were used. We found
that the study-created PTCA comparator group was worse
off than the published one, with commensurate impairments
in QoL as the patients with AF.
Two of the scales used in our analysis (Illness Intrusive-
ness and Symptom Severity Scales) are designed for patients
who have particular medical conditions. This, of course, is
not the case with respect to the healthy control populations.
Accordingly, the utility of the data from the healthy
population could be considered not relevant. We would only
argue that the inclusion of these scales, albeit modified for
the healthy, provide further validity to the data obtained.
Even though healthy patients should, by definition, have
little in the way of arrhythmia-related symptoms or illness
intrusiveness, their inclusion provides an opportunity to
assess “ceiling” effects for scales designed for patients with
actual conditions.
Conclusions. We have found that subjective health-related
QoL in patients with intermittent AF is significantly
impaired and commensurate with that in patients with
significant cardiac disease and much worse than healthy
controls. These impairments showed poor correlations with
more ‘objective’ indexes of AF disease severity. As well,
given that a host of investigational therapies for patients
with intermittent AF are now being assessed from tertiary
care referral centers, the data provided in this study allows
for sample size estimations for health QoL end points in the
assessment of therapies in AF.
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